FULCRUM THERAPEUTICS, INC. Earnings Per Share, Basic and Diluted
FULCRUM THERAPEUTICS, INC. (FULC) reported Earnings Per Share, Basic and Diluted of -$0.64 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-09
- FULCRUM THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.64.
- FULCRUM THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.57.
- FULCRUM THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.60.
- FULCRUM THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.54.
- FULCRUM THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2021 was -$2.29.
- FULCRUM THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2020 was -$2.79.
- FULCRUM THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2019 was -$8.13.
- FULCRUM THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2018 was -$31.14.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.64 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | -$2.29 10-K · filed 2022-03-03 | |||
| 2021-09-30 | -$0.57 10-Q · filed 2021-11-04 | -$1.71 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | -$0.60 10-Q · filed 2021-08-10 | -$1.14 10-Q · filed 2021-08-10 | ||
| 2021-03-31 | -$0.54 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | -$643.12 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$1338.42 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$1997.01 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$2.79 10-K · filed 2022-03-03 |
| 2020-09-30 | -$0.70 10-Q · filed 2021-11-04 | -$1355.65 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$2.16 10-Q · filed 2021-11-04 | -$2865.77 derived: net income ÷ weighted average shares · filed 2023-06-23 |
| 2020-06-30 | -$0.66 10-Q · filed 2021-08-10 | -$1.47 10-Q · filed 2021-08-10 | -$2173.94 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$3102.85 derived: net income ÷ weighted average shares · filed 2023-06-23 |
| 2020-03-31 | -$0.81 10-Q · filed 2021-05-06 | -$1519.65 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$2460.76 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$4202.66 derived: net income ÷ weighted average shares · filed 2023-06-23 |
| 2019-12-31 | -$707.61 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$1649.54 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$3535.73 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$8.13 10-K · filed 2021-03-04 |
| 2019-09-30 | -$0.97 10-Q · filed 2020-11-10 | -$3453.71 derived: net income ÷ weighted average shares · filed 2020-11-10 | -$10.33 10-Q · filed 2020-11-10 | -$15040.79 derived: net income ÷ weighted average shares · filed 2020-11-10 |
| 2019-06-30 | -$9.21 10-Q · filed 2020-08-11 | -$32.85 10-Q · filed 2020-08-11 | -$41504.58 derived: net income ÷ weighted average shares · filed 2020-08-11 | -$50417.01 derived: net income ÷ weighted average shares · filed 2020-08-11 |
| 2019-03-31 | -$24.29 10-Q · filed 2020-05-13 | -$32949.52 derived: net income ÷ weighted average shares · filed 2020-05-13 | -$41885.16 derived: net income ÷ weighted average shares · filed 2020-05-13 | -$50424.91 derived: net income ÷ weighted average shares · filed 2020-05-13 |
| 2018-12-31 | -$7850.81 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$15917.17 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$23469.71 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$31.14 10-K · filed 2020-03-05 |
| 2018-09-30 | -$8.08 10-Q · filed 2019-11-14 | -$15613.95 derived: net income ÷ weighted average shares · filed 2019-11-14 | -$23.28 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$7.50 10-Q · filed 2019-08-26 | -$15.14 10-Q · filed 2019-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |